User login
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community ( https://community.gastro.org ) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Brock Doubledee, DO: Xeljanz for Crohn’s
“I have a 20-year-old female with moderately active Crohn’s disease who has now failed Humira, Remicade, Entyvio and Stelara. The only option I know of for her at this time is Xeljanz, however her insurance will not approve this medication given its lack of FDA approval. I would be interested to know if anyone has any other recommended options or has had success with getting insurance approval. If you have had success I would appreciate any articles or guidance you have utilized to gain this approval.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24445.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community ( https://community.gastro.org ) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Brock Doubledee, DO: Xeljanz for Crohn’s
“I have a 20-year-old female with moderately active Crohn’s disease who has now failed Humira, Remicade, Entyvio and Stelara. The only option I know of for her at this time is Xeljanz, however her insurance will not approve this medication given its lack of FDA approval. I would be interested to know if anyone has any other recommended options or has had success with getting insurance approval. If you have had success I would appreciate any articles or guidance you have utilized to gain this approval.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24445.
Physicians with difficult patient scenarios regularly bring their questions to the AGA Community ( https://community.gastro.org ) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. Here’s a preview of a recent popular clinical discussion:
From Brock Doubledee, DO: Xeljanz for Crohn’s
“I have a 20-year-old female with moderately active Crohn’s disease who has now failed Humira, Remicade, Entyvio and Stelara. The only option I know of for her at this time is Xeljanz, however her insurance will not approve this medication given its lack of FDA approval. I would be interested to know if anyone has any other recommended options or has had success with getting insurance approval. If you have had success I would appreciate any articles or guidance you have utilized to gain this approval.”
See how AGA members responded and join the discussion: https://community.gastro.org/posts/24445.